The Study On Rapamycin-batroxobin Eluting Stent And Its Prevention Of Coronary Restenosis After Angiophaty

Restenosis is a main problem that feaze the CHD patient who accepted PCI. Although the use of stent reduced the restenosis occurred after PTCA, the restenosis rate in the stent still as high as 15%-25%. Drug eluting stent is a most important progress in preventing restenosis in recent years. Rapamycin eluting stent has been proved to have safe and efficient effect in preventing restenosis by a series of extensive and multi-centered randomized double-blind clinical experiments. But the results of SIRIUS experiments showed there were still 8.9% of the patients had the restenosis as well as common drug stent which could delay the endothelialization also had the chance to encounter the thrombokinesis within the stent (1%-3%). Patients who accepted the PCI need to take antiplatelet drag for such a long period that would bring them not only some side effects but also a big economic burden. To explore a new and effective drag eluting stent...